Incidence and Predictors of Neuropathic Pain Following Breast Surgery

Wilson, Gregory C.; Quillin, Ralph C.; Hanseman, Dennis J.; Lewis, Jaime D.; Edwards, Michael J.; Shaughnessy, Elizabeth

doi:10.1245/s10434-013-3156-6

Cited by 24 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26,35 Whether or not we incorporated missing data for nonsignificant predictors or converted categorical data for age and BMI to continuous data (Appendix 13, available at www.cmaj.ca/lookup/suppl/ doi:10.1503/cmaj.151276/-/DC1) did not appreciably influence the results. 42 Wilson et al, 2013 49 Mejdahl et al, 2013 26 Johansen et al, 2014 52 Lundstedt et al, 2012 41 De Oliveira et al, 2014 37 Steegers et al, 2008 44 Meretoja et al, 2014 58 Yang et al, 2010 51 Tasmuth et al, 1997 46 Shahbazi et al, 2015 60 Husen et al, 2006 40 Bell et al, 2014 59 Swenson et al …”

Section: Subgroup Analyses Meta-regression and Sensitivity Analysesmentioning

confidence: 99%

Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies

Wang

Guyatt

Kennedy

et al. 2016

CMAJ

242

239

View full text Add to dashboard Cite

D espite a 10-year survival rate of 83%, 1,2 between 25% and 60% of surviving patients who have undergone surgery for breast cancer experience persistent postsurgical pain, [3][4][5][6][7][8][9] which is associated with reduced quality of life and functional impairment. [10][11][12][13] Systematic reviews summarizing proposed risk factors for persistent pain after breast cancer surgery -including demographic, intraoperative and postoperative factors -have had several limitations, including outdated searches, inadequate attention to risk-of-bias assessment, lack of statistical pooling of measures of association and failure to evaluate the quality of evidence.5,10-14 We conducted a systematic review and meta-analysis of observational studies to identify risk factors for persistent pain after breast cancer surgery, addressing the limitations of previous reviews. MethodsWe completed our systematic review in accordance with the MOOSE statement 15 and registered our protocol with PROSPERO (registration CRD42014013338). Background: Persistent pain after breast cancer surgery affects up to 60% of patients. Early identification of those at higher risk could help inform optimal management. We conducted a systematic review and meta-analysis of observational studies to explore factors associated with persistent pain among women who have undergone surgery for breast cancer. Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies

show abstract

Section: Subgroup Analyses Meta-regression and Sensitivity Analysesmentioning

confidence: 99%

Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies

Wang

Guyatt

Kennedy

et al. 2016

CMAJ

242

239

View full text Add to dashboard Cite

show abstract

“…The content of measures that could be included within the core set should 1) span all dimensions of the ICF/ICF-CY (body structures and functioning, activity and participation, as well as personal and environmental issues), 2) include a combination of objective measures and subjective (self-report) measures, 75 3) contain measures that not only have good psychometric properties (reproducibility, validity, and responsiveness) but also should be able to cope with cross-cultural aspects of psychometric quality (culture, language), 4) be easy to use within clinical practice, independent of the setting in which it is being used, 5) be embedded into a clinical decision model/treatment regime to monitor the progression of the disease or treatment effects, and 6) distinguish between disabled patients and high-level performance athletes, as they may have other clinical profiles and may have musculoskeletal injury of a different nature.…”

Section: Part 2: Potential Solutions and Topics For Further Researchmentioning

confidence: 99%

Chronic pain in hypermobility syndrome and Ehlers–Danlos syndrome (hypermobility type): it is a challenge

Scheper¹,

Vries²,

Verbunt³

et al. 2015

JPR

View full text Add to dashboard Cite

Generalized joint hypermobility (GJH) is highly prevalent among patients diagnosed with chronic pain. When GJH is accompanied by pain in $4 joints over a period $3 months in the absence of other conditions that cause chronic pain, the hypermobility syndrome (HMS) may be diagnosed. In addition, GJH is also a clinical sign that is frequently present in hereditary diseases of the connective tissue, such as the Marfan syndrome, osteogenesis imperfecta, and the Ehlers-Danlos syndrome. However, within the Ehlers-Danlos spectrum, a similar subcategory of patients having similar clinical features as HMS but lacking a specific genetic profile was identified: Ehlers-Danlos syndrome hypermobility type (EDS-HT). Researchers and clinicians have struggled for decades with the highly diverse clinical presentation within the HMS and EDS-HT phenotypes (Challenge 1) and the lack of understanding of the pathological mechanisms that underlie the development of pain and its persistence (Challenge 2). In addition, within the HMS/EDS-HT phenotype, there is a high prevalence of psychosocial factors, which again presents a difficult issue that needs to be addressed (Challenge 3). Despite recent scientific advances, many obstacles for clinical care and research still remain. To gain further insight into the phenotype of HMS/EDS-HT and its mechanisms, clearer descriptions of these populations should be made available. Future research and clinical care should revise and create consensus on the diagnostic criteria for HMS/EDS-HT (Solution 1), account for clinical heterogeneity by the classification of subtypes within the HMS/EDS-HT spectrum (Solution 2), and create a clinical core set (Solution 3).

show abstract

“…Specifi c comorbidities have been shown to increase adverse effects of breast cancer therapy although most of this research has focused on the effects of obesity and related cardiovascular risk factors (Schmitz et al 2013 ). Diabetes for instance is a risk factor for paclitaxel neuropathy and increased risk of neuropathic pain following breast surgery (Lee and Swain 2006 ;Wilson et al 2013 ). Hypertension and obesity are risk factors for development of heart failure with trastuzumab, and development of postoperative lymphedema, fatigue and worse functional health (Schmitz et al 2013 ;Helyer et al 2010 ;Perez et al 2008 ).…”

Section: Impact Of Type Of Comorbiditiesmentioning

confidence: 99%

Comorbidities and Their Management: Potential Impact on Breast Cancer Outcomes

Hong

Ambrosone

Goodwin

2015

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Pre-existing comorbidities negatively impacts overall breast cancer prognosis, increasing both breast cancer specific deaths as well as death from competing causes. Improvements in breast cancer survival in recent decades, however, have primarily been experienced among cancer patients without comorbidities, and less so among those with moderate or severe comorbidities. As guidelines for the treatment of breast cancer are mostly based on studies excluding patients with moderate and severe comorbidities with under-representation of older women with comorbid conditions, information regarding treatment effectiveness in breast cancer patients with comorbidities is currently lacking. This chapter describes the impact of comorbidities on breast cancer treatment and outcomes, previous research approaches taken, and specific populations that may be most susceptible to the effects of comorbidities on breast cancer outcomes. Future research directions are suggested that may help to improve understanding of comorbidity-related factors that underlie disparities in breast cancer outcomes, and to examine the potential role of effective management of comorbidities among breast cancer patients as a strategy to help close gaps in disease prognosis.

show abstract

Incidence and Predictors of Neuropathic Pain Following Breast Surgery

Abstract: NPP is a significant risk following breast surgery. African American race, history of either diabetes mellitus or fibromyalgia, and treatment with taxane-based chemotherapy regimens are all associated with an increased risk of NPP.

Cited by 24 publications

References 19 publications

Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies

Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies

Chronic pain in hypermobility syndrome and Ehlers–Danlos syndrome (hypermobility type): it is a challenge

Comorbidities and Their Management: Potential Impact on Breast Cancer Outcomes

Contact Info

Product

Resources

About

Incidence and Predictors of Neuropathic Pain Following Breast Surgery

Abstract: NPP is a significant risk following breast surgery. African American race, history of either diabetes mellitus or fibromyalgia, and treatment with taxane-based chemotherapy regimens are all associated with an increased risk of NPP.

Cited by 24 publications

References 19 publications

Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies

Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies

Chronic pain in hypermobility syndrome and Ehlers&ndash;Danlos syndrome (hypermobility type): it is a challenge

Comorbidities and Their Management: Potential Impact on Breast Cancer Outcomes

Contact Info

Product

Resources

About

Chronic pain in hypermobility syndrome and Ehlers–Danlos syndrome (hypermobility type): it is a challenge